• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HAO Yaoting, LI Yanhui, ZHANG Huicong, et al. Research progress of nanocrystalline drugs in different drug delivery systems[J]. J China Pharm Univ, 2024, 55(4): 548 − 556. DOI: 10.11665/j.issn.1000-5048.2023111404
Citation: HAO Yaoting, LI Yanhui, ZHANG Huicong, et al. Research progress of nanocrystalline drugs in different drug delivery systems[J]. J China Pharm Univ, 2024, 55(4): 548 − 556. DOI: 10.11665/j.issn.1000-5048.2023111404
shu

Research progress of nanocrystalline drugs in different drug delivery systems

  • 1.

    School of Pharmacy, Hebei Medical University, Shijiazhuang 050031

  • 2.

    CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang 050000, China

More Information
  • Received Date: November 13, 2023
    Graphical Abstract
    • Abstract

  • Nanocrystal technology changes the solubility and dissolution rate of insoluble drugs by reducing the particle size to the nanometer level. This technology is not limited by carrier materials and encapsulation rate. It is suitable for a variety of drug delivery routes and easy for industrial production. It has gradually become a cutting-edge hot technology in the international pharmaceutical field to improve the absorption of insoluble drugs and improve their bioavailability. This article introduces the influencing factors and challenges of nanocrystal drugs (NC) in parenteral, ocular, transdermal and pulmonary administration, and focuses on nanocrystal drugs that have been marketed or are still in the preclinical or clinical trial stages of these delivery systems, in order to provide some insight for the further development of poorly soluble drug nanocrystal preparations.

    • FullText(HTML)
    • References (60)
  • [1]
    Tang KQ, Lin HQ, Li SH, et al. Advances in tumor targeted nanocrystals[J]. J China Pharm Univ(中国药科大学学报), 2020, 51(4): 418-424.
    [2]
    Rana S, Tomar D, Kaushik P, et al. Targeted approach to enhance the solubility of weakly soluble drugs by nanocrystal technology[J]. Pharm Nanotechnol, 2023, 11(5): 425-432. doi: 10.2174/2211738511666230504115640
    [3]
    Zhang ZN, Jin C, Zhang L, et al. Overview of stability research of nano-suspension[J]. J Shenyang Pharm Univ(沈阳药科大学学报), 2023. DOI: 10.14066/j.cnki.cn21-1349/r.2023.0152.
    [4]
    Ma YQ, Li G, Xiao HY, et al. Preparation technology of nanocrystals and research process in mucosal drug delivery[J]. Chin J Pharm(中国医药工业杂志), 2023, 54(7): 1042-1051.
    [5]
    Shi YJ, Lu A, Wang XY, et al. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives[J]. Acta Pharm Sin B, 2021, 11(8): 2396-2415. doi: 10.1016/j.apsb.2021.05.002
    [6]
    Ahire E, Thakkar S, Darshanwad M, et al. Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications[J]. Acta Pharm Sin B, 2018, 8(5): 733-755. doi: 10.1016/j.apsb.2018.07.011
    [7]
    Qin MD, Ye GY, Xin JH, et al. Comparison of in vivo behaviors of intramuscularly long-acting celecoxib nanosuspensions with different particle sizes for the postoperative pain treatment[J]. Int J Pharm, 2023, 636: 122793. doi: 10.1016/j.ijpharm.2023.122793
    [8]
    Jia LH, Xiao JC, Yang X, et al. Development and comparison of intramuscularly injected long-acting testosterone undecanoate nano-/microcrystal suspensions with three different particle size[J]. Iran J Pharm Res, 2021, 20(1): 307-317.
    [9]
    Ma LX, He Y, Bai LJ, et al. Preclinical studies of a high drug-loaded meloxicam nanocrystals injection for analgesia[J]. Colloids Surf B Biointerfaces, 2022, 218: 112777. doi: 10.1016/j.colsurfb.2022.112777
    [10]
    Qin MD, Xin JH, Han W, et al. Stabilizer-induced different in vivo behaviors for intramuscularly long-acting celecoxib nanocrystals[J]. Int J Pharm, 2022, 628: 122298. doi: 10.1016/j.ijpharm.2022.122298
    [11]
    Ibrahim MA, Shazly GA, Aleanizy FS, et al. Formulation and evaluation of docetaxel nanosuspensions: in-vitro evaluation and cytotoxicity[J]. Saudi Pharm J, 2019, 27(1): 49-55. doi: 10.1016/j.jsps.2018.07.018
    [12]
    Wang YL, Guo XY. Dantrolene—an orphan drug for malignant hyperthermia[J]. Prog Pharm Sci (药学进展), 2017, 41(8): 579-582.
    [13]
    Tian Y, Peng YF, Zhang ZW, et al. Research progress on preparation technology of nanocrystal drugs[J]. Acta Pharm Sinica(药学学报), 2021, 56(7): 1902-1910.
    [14]
    Quince Therapeutics. Quince therapeutics to acquire EryDel spa and its phase 3 asset targeting ataxia-telangiectasia with no currently approved treatments and estimated $1+ billion peak sales opportunity [EB/OL]. (2023-07-24) [2023-11-22]. https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-acquire-erydel-spa-and-its-phase-3-asset.
    [15]
    Acasti Pharma Inc. Safety and tolerability of GTX-104 compared with oral nimodipine in patients with aSAH - full text view - ClinicalTrials. gov [EB/OL]. (2023-12-05) [2024-01-07]. https://classic.clinicaltrials.gov/ct2/show/NCT05995405.
    [16]
    Zhang JL, Xu ZY, Dai WB, et al. Research progress of long-acting injections of aripiprazole[J]. Chin J Pharm(中国医药工业杂志), 2019, 5(10): 1153-1159.
    [17]
    Brii Biosciences Ltd. A study of BRII-296 in adults with severe postpartum depression (PPD) - full text view - ClinicalTrials. gov [EB/OL]. (2023-12-13) [2024-01-07]. https://classic.clinicaltrials.gov/ct2/show/NCT06057012.
    [18]
    He W, Zhang JF, Ju JL, et al. Preparation, characterization, and evaluation of the antitumor effect of kaempferol nanosuspensions[J]. Drug Deliv Transl Res, 2023, 13(11): 2885-2902. doi: 10.1007/s13346-023-01357-0
    [19]
    Fu XZ, Xu SJ, Li Z, et al. Enhanced intramuscular bioavailability of cannabidiol using nanocrystals: formulation, in vitro appraisal, and pharmacokinetics[J]. AAPS PharmSciTech, 2022, 23(3): 85. doi: 10.1208/s12249-022-02239-3
    [20]
    Ellipses Pharma Ltd. EP0057 in combination with olaparib in advanced ovarian cancer [EB/OL]. (2023-08-02) [2023-11-22]. https://classic.clinicaltrials.gov/ct2/show/NCT04669002.
    [21]
    Nippon Kayaku Co Ltd. A study of NK012 in patients with advanced metastatic triple negative breast cancer [EB/OL]. (2015-02-16) [2023-11-22]. https://classic.clinicaltrials.gov/ct2/show/NCT00951054.
    [22]
    Cristal Therapeutics. Dexamethasone (CriPec/nanoparticle/sustained release formulation, inflammatory disease) [EB/OL]. (2019-10-20) [2023-11-22]. https://www.cortellis.cn/intelligence/report/ci/nextgendrugall/75473.
    [23]
    Eagle Pharmaceuticals Inc. Eagle Pharmaceuticals provides 2022 business update and announces launch of vasopressin [EB/OL]. (2022-05-01) [2023-11-22]. https://investor.eagleus.com/news-releases/news-release-details/eagle-pharmaceuticals-provides-2022-business-update-and.
    [24]
    Mohammad IS, Hu HY, Yin LF, et al. Drug nanocrystals: fabrication methods and promising therapeutic applications[J]. Int J Pharm, 2019, 562: 187-202. doi: 10.1016/j.ijpharm.2019.02.045
    [25]
    Janagam DR, Wu LF, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye[J]. Adv Drug Deliv Rev, 2017, 122: 31-64. doi: 10.1016/j.addr.2017.04.001
    [26]
    Baba K, Hashida N, Tujikawa M, et al. The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes[J]. Int J Pharm, 2021, 592: 120067. doi: 10.1016/j.ijpharm.2020.120067
    [27]
    Wang CH, Pang Y. Nano-based eye drop: topical and noninvasive therapy for ocular diseases[J]. Adv Drug Deliv Rev, 2023, 194: 114721. doi: 10.1016/j.addr.2023.114721
    [28]
    Alshememry A, Alkholief M, Abul Kalam M, et al. Perspectives of positively charged nanocrystals of tedizolid phosphate as a topical ocular application in rabbits[J]. Molecules, 2022, 27(14): 4619. doi: 10.3390/molecules27144619
    [29]
    Romero GB, Keck CM, Müller RH, et al. Development of cationic nanocrystals for ocular delivery[J]. Eur J Pharm Biopharm, 2016, 107: 215-222. doi: 10.1016/j.ejpb.2016.07.005
    [30]
    Nagai N, Isaka T, Deguchi S, et al. In situ gelling systems using Pluronic F127 enhance corneal permeability of indomethacin nanocrystals[J]. Int J Mol Sci, 2020, 21 (19): 7083.
    [31]
    Peters MCC, Santos Neto ED, Monteiro LM, et al. Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems[J]. J Drug Target, 2020, 28(3): 259-270. doi: 10.1080/1061186X.2019.1663858
    [32]
    Xie GC, Lin SS, Wu F, et al. Nanomaterial-based ophthalmic drug delivery[J]. Adv Drug Deliv Rev, 2023, 200: 115004. doi: 10.1016/j.addr.2023.115004
    [33]
    Nicox Ophthalmics. Nicox announces results from the NCX 4251 phase 2b mississippi blepharitis trial [EB/OL]. (2021-09-23) [2023-11-22]. https://www.nicox.com/wp-content/uploads/EN_NCX-4251-Mississippi-results-PR_F_20210923.pdf .
    [34]
    Formosa Pharmaceuticals and AimMax Therapeutics. Formosa Pharmaceuticals and Aimmax Therapeutics announce the NDA submission to the US FDA for APP13007 for the treatment of post-operative inflammation and pain following ocular surgery [EB/OL]. (2023-05-04) [2023-11-22]. https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-the-nda-submission-to-the-us-fda-for-app13007-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery-301815496.html.
    [35]
    Oculis Ehf. First patient enrolled in LEOPARD, an investigator-initiated trial, with OCS-01 eye drops for the treatment of cystoid macular edema [EB/OL]. (2023-08-02) [2023-11-22]. https://www.globenewswire.com/news-release/2023/08/02/2716764/0/en/First-Patient-Enrolled-in-LEOPARD-an-Investigator-Initiated-Trial-with-OCS-01-Eye-Drops-for-the-Treatment-of-Cystoid-Macular-Edema.html.
    [36]
    Oculis Ehf. OCS-01, first investigational eye drop for front and back of the eye, met both primary endpoints in phase 3 OPTIMIZE trial with a once daily regimen for the treatment of inflammation and pain following cataract surgery [EB/OL]. (2023-08-02) [2023-11-22]. https://www.globenewswire.com/news-release/2023/08/08/2720376/0/en/OCS-01-First-Investigational-Eye-Drop-for-Front-and-Back-of-the-Eye-Met-Both-Primary-Endpoints-in-Phase-3-OPTIMIZE-Trial-with-a-Once-Daily-Regimen-for-the-Treatment-of-Inflammation.html.
    [37]
    Envisia Therapeutics. Envisia therapeutics initiates phase 2a clinical trial for ENV515 in patients with glaucoma [EB/OL]. (2015-01-27) [2023-11-22]. https://www.businesswire.com/news/home/20150127005303/en/Envisia-Therapeutics-Initiates-Phase-2a-Clinical-Trial-for-ENV515-in-Patients-with-Glaucoma.
    [38]
    BioNanoSim Ltd. Nano-Dexamethasone palmitate [EB/OL]. (2022-03-29) [2023-11-22]. https://www.cortellis.cn/intelligence/report/ci/nextgendrugall/142233.
    [39]
    BioNanoSim Ltd. Nano-Tacrolimus [EB/OL]. (2022-03-29) [2023-11-22]. https://www.cortellis.cn/intelligence/report/ci/nextgendrugall/139793.
    [40]
    Formica ML, Awde Alfonso HG, Paredes AJ, et al. Development of triamcinolone acetonide nanocrystals for ocular administration[J]. Pharmaceutics, 2023, 15(2): 683. doi: 10.3390/pharmaceutics15020683
    [41]
    Nandwani Y, Kaur A, Bansal AK. Generation of ophthalmic nanosuspension of prednisolone acetate using a novel technology[J]. Pharm Res, 2021, 38(2): 319-333. doi: 10.1007/s11095-021-02985-2
    [42]
    Corrias F, Schlich M, Sinico C, et al. Nile red nanosuspensions as investigative model to study the follicular targeting of drug nanocrystals[J]. Int J Pharm, 2017, 524(1/2): 1-8.
    [43]
    Ahmed IS, Elnahas OS, Assar NH, et al. Nanocrystals of fusidic acid for dual enhancement of dermal delivery and antibacterial activity: in vitro, ex vivo and in vivo evaluation[J]. Pharmaceutics, 2020, 12(3): 199. doi: 10.3390/pharmaceutics12030199
    [44]
    Wu X, Landfester K, Musyanovych A, et al. Disposition of charged nanoparticles after their topical application to the skin[J]. Skin Pharmacol Physiol, 2010, 23(3): 117-123. doi: 10.1159/000270381
    [45]
    Abbate MTA, Ramöller IK, Sabri AH, et al. Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND)[J]. Int J Pharm, 2023, 640: 123005. doi: 10.1016/j.ijpharm.2023.123005
    [46]
    UMeWorld Ltd. AlphaRx launches Indaflex™ to Mexican physicians [EB/OL]. (2018-08-29) [2023-11-22]. https://www.cortellis.cn/intelligence/report/ci/nextgendrugall/52823.
    [47]
    Lacouture ME, Goldfarb SB, Markova A, et al. Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer[J]. Breast Cancer Res Treat, 2022, 194(1): 57-64. doi: 10.1007/s10549-022-06584-6
    [48]
    Najm MB, Rawas-Qalaji M, Assar NH, et al. Optimization, characterization and in vivo evaluation of mupirocin nanocrystals for topical administration[J]. Eur J Pharm Sci, 2022, 176: 106251. doi: 10.1016/j.ejps.2022.106251
    [49]
    Li L, Liu C, Fu J, et al. CD44 targeted indirubin nanocrystal-loaded hyaluronic acid hydrogel for the treatment of psoriasis[J]. Int J Biol Macromol, 2023, 243: 125239. doi: 10.1016/j.ijbiomac.2023.125239
    [50]
    Tekko IA, Permana AD, Vora L, et al. Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: potential for enhanced treatment of psoriasis[J]. Eur J Pharm Sci, 2020, 152: 105469. doi: 10.1016/j.ejps.2020.105469
    [51]
    Biodexa Pharmaceuticals plc. Midatech pharma plc results for the year ended 31 December 2020 [EB/OL]. (2021-04-30) [2023-11-22]. https://www.biospace.com/article/releases/midatech-pharma-plc-announces-results-for-the-year-ended-31-december-2020/.
    [52]
    Kumar M, Jha A, Dr M, et al. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy[J]. Expert Opin Drug Deliv, 2020, 17(10): 1459-1472. doi: 10.1080/17425247.2020.1798401
    [53]
    He Y, Liang YM, Mak JCW, et al. Size effect of curcumin nanocrystals on dissolution, airway mucosa penetration, lung tissue distribution and absorption by pulmonary delivery[J]. Colloids Surf B Biointerfaces, 2020, 186: 110703. doi: 10.1016/j.colsurfb.2019.110703
    [54]
    Yu MR, Wang JL, Yang YW, et al. Rotation-facilitated rapid transport of nanorods in mucosal tissues[J]. Nano Lett, 2016, 16(11): 7176-7182. doi: 10.1021/acs.nanolett.6b03515
    [55]
    Costabile G, Provenzano R, Azzalin A, et al. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection[J]. Nanomed-Nanotechnol Biol Med, 2020, 23: 102113. doi: 10.1016/j.nano.2019.102113
    [56]
    Murgia X, Pawelzyk P, Schaefer UF, et al. Size-limited penetration of nanoparticles into porcine respiratory mucus after aerosol deposition[J]. Biomacromolecules, 2016, 17(4): 1536-1542. doi: 10.1021/acs.biomac.6b00164
    [57]
    Huang GT, Shuai SY, Zhou WC, et al. To enhance mucus penetration and lung absorption of drug by inhalable nanocrystals-In-microparticles[J]. Pharmaceutics, 2022, 14(3): 538. doi: 10.3390/pharmaceutics14030538
    [58]
    Johnston W, Verco J, DiZerega G, et al. Enhanced tumor regression and immune cell infiltration by inhaled submicron particle paclitaxel in an orthotopic athymic nude rat model of non-small cell lung cancer (NSCLC) [EB/OL]. (2019-05-01) [2023-11-22]. https://xueshu.baidu.com/usercenter/paper/show?paperid=170w0e70t26y0g302u0k0xd01j748054&site=xueshu_se.
    [59]
    Casula L, Lai F, Pini E, et al. Pulmonary delivery of curcumin and beclomethasone dipropionate in a multicomponent nanosuspension for the treatment of bronchial asthma[J]. Pharmaceutics, 2021, 13(8): 1300. doi: 10.3390/pharmaceutics13081300
    [60]
    Zhang SY, Yan S, Lu KW, et al. Spray freeze dried niclosamide nanocrystals embedded dry powder for high dose pulmonary delivery[J]. Powder Technol, 2023, 415: 118168. doi: 10.1016/j.powtec.2022.118168
    • Related Articles

  • Related Articles

    [1]CHEN Ling-ping, L Wen-li, PING Qi-neng. Preparation and bioavailability of bupropion hydrochloride sustained-release pellets[J]. Journal of China Pharmaceutical University, 2009, 40(5): 421-425.
    [2]Pharmacokinetics and Bioavailability of Cinnamic Acid in Mice[J]. Journal of China Pharmaceutical University, 2004, (4): 38-40.
    [3]Pharmacokinetics and Relative Bioavailability of Medroxypro gesterone Capsules and Tablets in Healthy Male Volunteers[J]. Journal of China Pharmaceutical University, 2001, (6): 26-28.
    [4]Pharmacokinetics and Relative Bioavailability of Gliquidone Capsules and Tablets[J]. Journal of China Pharmaceutical University, 2000, (6): 19-21.
    [5]Pharmacokinetics andRelative Bioavailability of Sustained-release Felodipine Capsule in Healthy Volunteers[J]. Journal of China Pharmaceutical University, 2000, (3): 26-29.
    [6]Pharmacokinetics and Relative Bioavailability of Enalapril Maleate in Healthy Volunteers[J]. Journal of China Pharmaceutical University, 1999, (5): 350-352.
    [7]Study on Pharmacokinetics and Relative Bioavailability of Cefaclor Sustained Release Tablets in 8 Chinese Healthy Subjects[J]. Journal of China Pharmaceutical University, 1998, (5): 29-32.
    [8]Pharmacokinetics and Relative Bioavailability of Cyclosporin Pearls in Healthy Volunteers[J]. Journal of China Pharmaceutical University, 1996, (6): 20-22.
    [9]Pharmacokinetics and Relative Bioavailability of Tamoxifen in Healthy Volunteers[J]. Journal of China Pharmaceutical University, 1995, (2): 84-86.
    [10]Pharmacokinetics and Bioavailability of Ribavirin in 9 Chinese Healthy Volunteers[J]. Journal of China Pharmaceutical University, 1994, (6): 325-327.

Catalog

    Get Citation
    PDF
    XML
    Article views (825) PDF downloads (47) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：297540

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return